gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MNOVHealthcarePharmaceuticals

Medicinova, Inc. (MNOV)

$1.45+2.11%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.45▲ 2.11% in range
Nov 4, 2025Low $1.23 · High $3.45Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Medicinova closed at $1.45 on Nov 4, up 2.11%, 58.0% below its 52-week closing high. Volume of 50.0K shares was 0.79× its 20-day average (below normal).

Split-adjusted performance: -12.1% over one month, +0.0% over six months, -3.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $458.44K, up 240.6% from a year earlier, with a net margin of -504.8%.

Short interest was 292.3K shares at the Oct 15 settlement, down 13.8% from the prior report (0.7% of float, 2.2 days to cover).

Market cap$71.4M49.2M shares
Revenue · quarter$458.4K+240.6% YoY
Diluted EPS$-0.05—
P/E · TTM—P/S 77.5×
Net margin-504.8%Gross 100.0%
Dividend yieldNone
52-week range1.23 – 3.45−58.0% from high
Volume50.0K0.79× 20-day avg
Volatility · 60d114.6%Annualised
Short % of float0.7%2.2 days to cover
Net cash$25.4MCash $25.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.4%1M −12.1%3M +6.6%6M 0.0%YTD +10.7%1Y −3.3%3Y −26.0%5Y −58.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum72
Revenue growth90
Net margin30
Value (low P/E)—
Size38

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short292.3K−13.8% vs prior
Days to cover2.2Settled Oct 15
% of float0.7%
Short vol. 10d50.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MNOVMedicinova$1.45+2.11%0.0%+240.6%−504.8%—$71.4M
PMVPPMV Pharmaceuticals$1.33−3.99%−8.6%———$70.8MCompare
COYACoya Therapeutics$3.08−0.96%−27.4%+49.0%−2723.4%—$72.3MCompare
MAIAMAIA Biotechnology$1.14+5.56%−15.6%———$70.4MCompare
CRBPCorbus Pharmaceuticals Holdings$3.57−7.75%−67.3%———$69.0MCompare
ACRVAcrivon Therapeutics$1.74+4.19%−16.7%———$74.6MCompare
LFVNLifevantage Corporation Common Stock (Delaware)$5.97+3.65%−0.5%−23.1%3.0%14.8$75.2MCompare
TENXTenax Therapeutics$1.81−1.63%−84.9%———$67.7MCompare
CPIXCumberland Pharmaceuticals$4.44+3.02%+1.6%−56.3%−2569.0%—$66.5MCompare

News about Medicinova

All news →
MediciNova CEO Provides Shareholder UpdateGlobeNewswire Inc. · Oct 12, 2026NeutralMediciNova to Participate in the Maxim Growth SummitGlobeNewswire Inc. · Oct 6, 2026▲ PositiveMediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)GlobeNewswire Inc. · Sep 28, 2026▲ PositiveMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)GlobeNewswire Inc. · May 26, 2026▲ PositiveNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationGlobeNewswire Inc. · Apr 27, 2026▲ Positive

Quick answers

What does Medicinova do?
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
What is MNOV's market cap?
$71.37M, based on the Nov 4 close of $1.45.
Does Medicinova pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MNOV is sold short?
292.3K shares, 0.7% of float, as of Oct 15, 2026.
What sector is MNOV in?
Healthcare, in the Pharmaceuticals industry.

About Medicinova

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

HQ: La Jolla, CA6 employeesListed Dec 7, 2006medicinova.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology